Delving into the Latest Updates on COM-701 with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

CGEN-15029, COM 701, COM701/PVRIG

Target

CD112R

Action

antagonists

Mechanism

CD112R antagonists(Transmembrane protein PVRIG antagonists)

Therapeutic Areas

NeoplasmsEndocrinology and Metabolic DiseaseUrogenital Diseases+ [2]

Active Indication

Platinum-sensitive epithelial ovarian cancerRecurrent ovarian cancerSquamous Cell Carcinoma of Head and Neck+ [2]

Inactive Indication

Advanced cancerAdvanced Malignant Solid NeoplasmBRCA-mutated Ovarian Cancer+ [7]

Originator Organization

Compugen, Inc.

Active Organization

Compugen Ltd.

Bristol Myers Squibb Co.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

The goal of this clinical trial is to learn if the experimental antibody COM701 delays the progression of ovarian cancer in participants with Relapsed Platinum Sensitive Ovarian Cancer. It will also learn about the safety of COM701.
The main questions the trial aims to answer are:
* Does COM701, when used as a maintenance treatment, stop or slow the progression of ovarian cancer?
* Does COM701 delay the time to needing a new anti-cancer treatment?
* What side effects do participants have when taking COM701?
Participants will:
* Visit the clinic once every 3 weeks during which the study treatment will be administered intravenously
* Undergo various tests and procedures to monitor general health throughout the trial including physical examinations, vital sign measurements (heart rate, blood pressure, breathing, and body temperature), weight measurements, electrocardiography (ECG), blood and urine tests and pregnancy tests if relevant.
* Undergo various tests and procedures to assess disease response throughout the trial including tumor imaging by CT scans or MRI to assess the tumor, its location, and size, and the testing of a sample of tumor tissue (from a prior biopsy or a fresh biopsy if feasible, to evaluate tumor response to treatment and to measure levels of tumor markers,

Start Date21 Jul 2025

Sponsor / Collaborator

Compugen Ltd.

NCT04570839

/ CompletedPhase 1/2

A Phase 1/2 Study Evaluating the Safety, Tolerability and Preliminary Antitumor Activity of COM701 in Combination With BMS-986207 (Anti-TIGIT Antibody) and Nivolumab in Subjects With Advanced Solid Tumors.

This is a phase 1/2 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM701 in combination with BMS-986207 and nivolumab in patients with advanced solid tumors.

Start Date31 Aug 2020

Sponsor / Collaborator

Compugen Ltd.

[+1]

NCT04354246

/ CompletedPhase 1

A Phase 1 Study of The Safety and Tolerability of COM902 in Subjects With Advanced Malignancies

Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies.

Start Date31 Mar 2020

Sponsor / Collaborator

Compugen Ltd.

100 Clinical Results associated with COM-701

Login to view more data

100 Translational Medicine associated with COM-701

Login to view more data

100 Patents (Medical) associated with COM-701

Login to view more data

1

Literatures (Medical) associated with COM-701

01 Jun 2020·Cancer discoveryQ1 · MEDICINE

COM701 Shows Antitumor Activity, +/− Nivolumab

Q1 · MEDICINE

Article

Abstract:

According to results from an ongoing phase I trial, the novel immune checkpoint inhibitor COM701, which targets PVRIG, has shown early signs of efficacy, on its own and combined with nivolumab, in patients with a variety of advanced solid tumors.

106

News (Medical) associated with COM-701

12 May 2026

·www.prnewswire.com

Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum

HOLON, Israel, May 12, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will present at the 2026 Stifel Virtual Targeted Oncology Forum. The presentation will take place on Tuesday, May 19, 2026, at 10:00-10:25 AM ET. A live webcast will be accessible on the Investor Relations section of the Compugen website at . A replay will also be available following the live event. About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI/ML powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig and GS-0321 (previously COM503). COM701, a potential first-in-class anti-PVRIG antibody, and COM902, an anti-TIGIT antibody, have been evaluated for the treatment of solid tumors as monotherapy and in combinations. Currently, Compugen is conducting a blinded randomized ovarian cancer platform trial evaluating COM701 as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902 program, is being developed by AstraZeneca pursuant to an exclusive license agreement between Compugen and AstraZeneca and is being evaluated in multiple Phase 3, Phase 2 and Phase 1 clinical trials. GS-0321 (previously COM503), Compugen's potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, is licensed to Gilead and is being evaluated in a Phase 1 clinical trial that Compugen is conducting. In addition, Compugen's has an early-stage immuno-oncology pipeline consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. Company contact: Investor relations Email: [email protected] Tel: +1 (628) 241-0071 SOURCE Compugen Ltd. 21% more press release views with Request a Demo

ImmunotherapyPhase 1License out/inPhase 2Phase 3

04 May 2026

·www.prnewswire.com

Compugen to Release First Quarter 2026 Results on Monday, May 18, 2026

HOLON, Israel, May 4, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the Company will release its first quarter 2026 financial results on Monday, May 18, 2026, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, which is located at the following link. Following the live webcast, a replay will be available on the Company's website. About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI/ML powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig and GS-0321 (previously COM503). COM701, a potential first-in-class anti-PVRIG antibody, and COM902, a potential best-in-class therapeutic anti-TIGIT antibody, have been evaluated for the treatment of solid tumors as monotherapy and in combinations of dual (PVRIG/PD-1, PVRIG/TIGIT) and triple (PVRIG/PD-1/TIGIT) blockade. Currently, the only clinical trial we sponsor and are conducting is a blinded randomized ovarian cancer platform trial evaluating COM701 as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902 program, is being developed by AstraZeneca pursuant to an exclusive license agreement between us and AstraZeneca and is being evaluated in multiple Phase 3, Phase 2 and Phase 1 clinical trials. GS-0321 (previously COM503), Compugen's potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, is licensed to Gilead and is being evaluated in a Phase 1 clinical trial that we sponsor and are conducting. In addition, Compugen's has an early-stage immuno-oncology pipeline consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. Company Contact: Investor relations Email: [email protected] Tel: +1 (628) 241-0071 SOURCE Compugen Ltd. 21% more press release views with Request a Demo

License out/inPhase 1ImmunotherapyPhase 2Financial Statement

09 Apr 2026

·www.prnewswire.com

Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference

HOLON, Israel, April 9, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference. The presentation will take place on Monday, April 13, 2026, at 8:45-9:25 AM ET. A live webcast will be accessible on the Investor Relations section of the Compugen website at . A replay will also be available following the live event. About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable AI/ML powered computational discovery platform (Unigen™) to identify novel drug targets and biological pathways for developing cancer immunotherapies. Compugen has two differentiated Fc-reduced programs targeting TIGIT: COM902, a fully owned Fc-reduced high affinity anti-TIGIT antibody in Phase 1 development and rilvegostomig, an Fc-reduced PD-1/TIGIT bispecific antibody in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. The TIGIT component of rilvegostomig is derived from COM902. In Phase 1 development Compugen has COM701, a potential first-in-class anti-PVRIG Fc-reduced antibody and GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address new mechanisms to activate the immune system against cancer. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. Company contact: Investor relations Email: [email protected] Tel: +1 (628) 241-0071 SOURCE Compugen Ltd. 21% more press release views with Request a Demo

ImmunotherapyPhase 1License out/in

100 Deals associated with COM-701

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Platinum-sensitive epithelial ovarian cancer	Phase 2	United States	Compugen Ltd.	21 Jul 2025
Platinum-sensitive epithelial ovarian cancer	Phase 2	France	Compugen Ltd.	21 Jul 2025
Platinum-sensitive epithelial ovarian cancer	Phase 2	Israel	Compugen Ltd.	21 Jul 2025
Recurrent ovarian cancer	Phase 2	United States	Compugen Ltd.	21 Jul 2025
Recurrent ovarian cancer	Phase 2	France	Compugen Ltd.	21 Jul 2025
Recurrent ovarian cancer	Phase 2	Israel	Compugen Ltd.	21 Jul 2025
Advanced Malignant Solid Neoplasm	Phase 2	United States	Compugen Ltd.	31 Aug 2020
Endometrial Carcinoma	Phase 2	United States	Compugen Ltd.	31 Aug 2020
Platinum-Resistant Epithelial Ovarian Carcinoma	Phase 2	United States	Compugen Ltd.	31 Aug 2020
Platinum-Resistant Ovarian Carcinoma	Phase 2	United States	Compugen Ltd.	31 Aug 2020

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


CPG-02-101 (SITC2024)	Phase 1	Platinum-Resistant Ovarian Carcinoma	25	COM701 15 mg/kg + COM902 3 mg/kg + Pembrolizumab 200 mg Q3W	sntykgrpmh(dyqdousgkt) = Majority of AEs were of ≤2 grade in severity. No grade 4/5 events were reported. One grade 3 event of serious immune related encephalopathy was reported in one pt, which was resolving following treatment with steroids gubifwcfqr (zajwsafvaw ) View more	Positive	05 Nov 2024
NCT04354246 (ASCO2024)	Phase 1	Colorectal Liver Metastases	20	COM701 15 mg/kg + COM902 3 mg/kg + pembrolizumab 200 mg	uhsuczcxcl(tmouwjcwqu) = Treatment related AEs were reported in 11/20 [55%] pts, the majority were ≤G2 7/20 [35%] with the most frequent TRAE of 4 pts each with ≤G2 fatigue, myalgia, 4/20 pts with G3 TRAE, there were no ≥G4 TRAEs cnmnuxqhfr (ljpvyaybqw )	Positive	24 May 2024
NCT04570839 (ASCO2023) Manual	Phase 1/2	Endometrial Carcinoma Microsatellite Stable (MSS)	9	COM701 20 mg/kg+BMS-986207 480 mg+nivolumab 480 mg	hpbcvlohbb(hisfsjccqp) = ukwxvpbpxf ugkyszsbhu (imxktxizfu ) View more	Positive	31 May 2023
NCT04570839 (ESMO_IO2022) Manual	Phase 1/2	Platinum-Resistant Ovarian Carcinoma	20	nivolumab+BMS 986207+COM701	ralpncwygp(rvtrxfjnph) = jtircybesd sqxdqbnzju (tgtnnjsodp ) View more	Positive	08 Dec 2022
NCT03667716 (ESMO_IO2022) Manual	Phase 1	Platinum-Resistant Epithelial Ovarian Carcinoma	20	nivolumab+COM701	zvybbuqese(wzfltmulxq) = nausea 11 pts, fatigue 11 pts xsmkkaiegv (ipbfgxxegg )	Positive	08 Dec 2022
NCT03667716 (ESMO_IO2022)	Phase 1	metastatic non-small cell lung cancer PD-1/PD-L1 inhibitor	7	COM701 monotherapy	tdmebggdoa(lklempvwcq) = qpbnuzniir irvtpeiykl (thvbyhqhur, [2.7 - 11.6]) View more	-	08 Dec 2022
				COM701 + nivolumab	tdmebggdoa(lklempvwcq) = yagagjwscy irvtpeiykl (thvbyhqhur, [8.6 - NE])
NCT04570839 (478, SITC2021)	Phase 1	Advanced Malignant Solid Neoplasm	14	COM701 0.3 mg/kg	zsqhretjgp(jaugxgffay) = 2 pts (14%) with G3 abdominal pain gsxdvqxgzp (bdkbixruua ) View more	Positive	10 Nov 2021
				COM701 1 mg/kg
NCT03667716 (ASCO 12021 \| ASCO 22021) Manual	Phase 1	Advanced Malignant Solid Neoplasm Last line	51	COM701 (Arm A)	lujrpygqmq(khxcisejdh) = pts on COM701 mono (N=38)- No AE (4), Grade≤2 (21), G3 (11), G4 (1), G5 (1, PD), pts on combo (N=16) - Grade≤2 (8), G3 (7), G5 (1, PD) evswjpfdux (meelgxdwhm ) View more	Positive	20 May 2021
				COM701+nivolumab (Arm B)
NCT03667716 (P421, SITC2019)	Phase 1	Advanced Malignant Solid Neoplasm	13	COM701 0.01 mg/kg	tegrhdvmyd(abtzpicyod) = abdominal pain (6%) gheiuzoihw (kllpwbilwp ) View more	Positive	01 Nov 2019
				COM701 0.03 mg/kg

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data